Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/gutjnl-2015-311079 http://scihub22266oqcxt.onion/10.1136/gutjnl-2015-311079 C5531223!5531223!26893500     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Gut 2017 ; 66 (5): 839-51 Nephropedia Template TP {{tp|p=26893500|t=2017. The safety of vedolizumab for ulcerative colitis and Crohn s disease |pdf=|usr=}}{{26893500}} gab.com Text The safety of vedolizumab for ulcerative colitis and Crohn s disease JO: Gut http://www.kidney.de/pget.php?&tw=1&pmid=26893500 #FOAvip Objective: Vedolizumab is a gut-selective antibody to ?4?7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design: Safety data (May 2009?June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ?1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results: In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1?1977?days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (?0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor ? antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ?5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions: Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number: NCT01177228, NCT00619489, NCT00783718, NCT00783692, NCT01224171, NCT00790933. Twit Text FOAVip The safety of vedolizumab for ulcerative colitis and Crohn s disease ????Gut http://www.kidney.de/pget.php?&tw=1&pmid=26893500 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26893500 #FOAvip English Wikipedia <ref>{{Cite pmid|26893500}}</ref> The safety of vedolizumab for ulcerative colitis and Crohn s disease #MMPMID26893500 Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG Gut 2017[May]; 66 (5): 839-51 PMID26893500show ga Objective: Vedolizumab is a gut-selective antibody to ?4?7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design: Safety data (May 2009?June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ?1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results: In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1?1977?days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (?0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor ? antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ?5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions: Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number: NCT01177228, NCT00619489, NCT00783718, NCT00783692, NCT01224171, NCT00790933. äThe safety of vedolizumab for ulcerative colitis and Crohn s disease (epmc).pdf DeepDyve Pubget Overpricing